Delivery Order SPE2DB20D3303-SPE2DB25FA3EA
- Not listed
- The Defense Logistics Agency awarded a $2,090.75 delivery order to AmerisourceBergen Drug Corp for supply of Dupixent 300 mg/2 ml syringes on July 30, 2025. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to the company's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $16,259.88 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes, with an ultimate completion date of August 28, 2025. This competitively awarded contract, with no set-aside designation, is being performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle that enables AmerisourceBergen to...
- The Defense Logistics Agency awarded a $19,651.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of August 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a single transaction under the company's...
- The Defense Logistics Agency awarded a $47,704.56 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $11,735.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a $29,915.39 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes under a firm fixed price contract. The award was issued on August 11, 2025, with an ultimate completion date of August 12, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this medical supply delivery order. This delivery order operates as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 29, 2025, with an ultimate completion date of July 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be supplied from the vendor's location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $7,211.22 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This competitively awarded, firm fixed-price delivery order is expected to be completed by July 30, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $72,558.04. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order under the...
- The Defense Logistics Agency awarded a $17,566.90 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed price delivery order represents a non-set-aside competitive award supporting the federal medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for the Department of Defense and...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3EADelivery Order
The Defense Logistics Agency awarded a $17,597.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes, with an ultimate completion date of September 3, 2025. This non-set-aside delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The product will be performed at the contractor's Conshohocken, Pennsylvania location, which serves as the company's corporate headquarters and primary distribution hub for federal pharmaceutical procurement activities. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves critical federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive contract portfolio with the DLA demonstrates its capability to supply a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.6k | 9/2/25 |